This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Trillium Therapeutics Inc.

Drug Names(s): Ovidrel (human Chorionic Gonadotropin, hCG) and Epogen (erythropoietin, EPO)

Description: NTx-265 is a therapeutic regimen of two drugs, subcutaneuos human Chorionic Gonadotropin (hCG) and intravenous Erythropoietin (EPO). hCG is the first drug administered in the regimen, and aims to increase the number of neural stem cells (NSCs) located in the brain of a patient suffering from a recent stroke. EPO is the second drug administered in the regimen, and aims to promote the differentiation of these newly formed NSCs into new neurons. New neurons thus formed are anticipated to provide benefit to the patient through the replacement of the brain cells that were lost or damaged by the stroke.

Deal Structure: Neurogenesis Biotech originally developed NTx-265.

In October 2004, Transition Therapeutics sold its subsidiary Stem Cell Therapeutics to Neurogenesis Biotech Corp for upfront and anniversary payments totaling $3.5 million. The agreement also includes royalties on sales and other income.

Later in October 2004, Neurogenesis Biotech Corp announced that it has changed its name to Stem Cell Therapeutics Corp.

Stem Cell and Trillium
In June 2014, Stem Cell Therapeutics announced that it has filed articles of amalgamation to merge with its wholly-owned subsidiary Trillium Therapeutics Inc. (TTI). The combined company has adopted the Trillium name.

Trillium and Fluorinov
In January 2016, Trillium announced that it has acquired all of the outstanding shares of Fluorinov Pharma Inc., a privately-held oncology company.Under the terms of the agreements, Trillium has agreed to acquire all of the outstanding shares of Fluorinov for an upfront payment of C$10...See full deal structure in Biomedtracker

NTx-265 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug